IR News

Oct. 31, 2022Print(PDF/136KB)Finances

Notice Concerning Finance Income

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; Securities Code: 4506, Prime Market of TSE) announced today that it has recorded finance income for the second quarter of the fiscal year ending March 31, 2023 (from April 1, 2022 to September 30, 2022) as follows.

1. Details of Finance Income
The Company has recorded a foreign exchange gain of 49,655 million yen under finance income for the second quarter of the fiscal year ending March 31, 2023 due to recent fluctuations in foreign exchange rates. This was mainly due to the valuation of assets denominated in foreign currencies.

2. Future Outlook
Regarding the impact of the above finance income on the results of the Company operations, please refer to the "Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2023 [IFRS]" announced today. In addition, although the amount of foreign exchange gains will fluctuate due to future exchange rates, the Company has factored a certain amount of foreign exchange gains into the revised financial forecasts announced today.